Self-Reported Delayed Adverse Events and Flare Following COVID-19 Vaccination Among Patients With Autoimmune Rheumatic Disease (AIRD) in Malaysia: Results From the COVAD-2 Study
Articolo
Data di Pubblicazione:
In Stampa
Abstract:
Objectives: To determine the prevalence of self-reported delayed adverse events (DAEs), major AEs, and flares following COVID-19 vaccinations among patients with autoimmune rheumatic diseases (AIRDs) in Malaysia.
Methodology: An electronically validated survey from the COVID-19 vaccination in autoimmune diseases (COVAD) study group was distributed in July 2021 to patients with autoimmune diseases and healthy controls (HCs). The survey collected data on DAEs (any AE that persisted or occurred after 7 days of vaccination), any early or delayed major adverse events (MAEs), and flares following COVID-19 vaccination. Generalized estimating equation (GEE) models were performed to determine the factors associated with repeated events of DAEs, MAEs, and flares.
Results: A total of 556 vaccines were administered to 204 subjects (150 AIRDs and 54 HCs), with 72.1% completing 3 doses. In multivariate GEE analysis, there was a greater frequency of minor DAEs among AIRDs versus HCs (OR 5.65, p = 0.052). The occurrence of MAEs was higher in AIRDs versus HCs (4.9% vs. 1.3%, p = 0.052), but it was no longer significant in the GEE model. In the AIRDs group, the BNT162b2 vaccine increased the risk for minor DAEs (OR4.68, p = 0.02) while patients with autoimmune multimorbidity showed a greater risk for MAEs (OR 8.25, p = 0.007). The rate of flare was 10.6% and multivariate GEE analysis revealed that The rate of flare was 10.6% and multivariate GEE analysis revealed that systemic lupus erythematosus (SLE) (OR0.31, p = 0.03) and hydroxychloroquine (HCQ) (OR 0.16, p < 0.001) were protective against flare.
Conclusion: The rates of minor DAEs, major AEs, and flares were comparable with other reported studies. Different types of vaccines, underlying AIRDs, and treatments may influence the symptoms of AEs and flares postvaccination against COVID-19.
Methodology: An electronically validated survey from the COVID-19 vaccination in autoimmune diseases (COVAD) study group was distributed in July 2021 to patients with autoimmune diseases and healthy controls (HCs). The survey collected data on DAEs (any AE that persisted or occurred after 7 days of vaccination), any early or delayed major adverse events (MAEs), and flares following COVID-19 vaccination. Generalized estimating equation (GEE) models were performed to determine the factors associated with repeated events of DAEs, MAEs, and flares.
Results: A total of 556 vaccines were administered to 204 subjects (150 AIRDs and 54 HCs), with 72.1% completing 3 doses. In multivariate GEE analysis, there was a greater frequency of minor DAEs among AIRDs versus HCs (OR 5.65, p = 0.052). The occurrence of MAEs was higher in AIRDs versus HCs (4.9% vs. 1.3%, p = 0.052), but it was no longer significant in the GEE model. In the AIRDs group, the BNT162b2 vaccine increased the risk for minor DAEs (OR4.68, p = 0.02) while patients with autoimmune multimorbidity showed a greater risk for MAEs (OR 8.25, p = 0.007). The rate of flare was 10.6% and multivariate GEE analysis revealed that The rate of flare was 10.6% and multivariate GEE analysis revealed that systemic lupus erythematosus (SLE) (OR0.31, p = 0.03) and hydroxychloroquine (HCQ) (OR 0.16, p < 0.001) were protective against flare.
Conclusion: The rates of minor DAEs, major AEs, and flares were comparable with other reported studies. Different types of vaccines, underlying AIRDs, and treatments may influence the symptoms of AEs and flares postvaccination against COVID-19.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Keywords: COVID‐19 vaccine; autoimmunity; flares; quality of life.
Elenco autori:
Shaharir, Ss; Nawi, Am; Mariamutu, Tn; Kamaruzaman, L; Msm, Said; Rajalingham, S; Parodis, I; Sarkar, M; Shinjo, Sk; Kadam, E; Ziade, N; Tan, Cl; Gullemin, F; Caballero-Uribe, Cv; Tan, Al; Andreoli, L; Parihar, J; Yaadav, P; Saha, S; COVAD Study Group, ; Gupta, L; OVAD Study Group: Steering Committee:Elena Nikiphorou, Agarwal V.; Parodis, Ioannis; Velikova, Tsvetelina; Gracia-Ramos, Abrahamedgar; Kuwana, Masataka; Knitza, Johannes; Ashimamakol, ; Carlos Enrique Toro Gutiérrez, ; Dey, Dzifa; Day, Jessica; Wincup, Chris; Dalbeth, Nicola; Burmester, Gerd-Rüdiger; Gouchunwang, ; Study Group Members: Bhupen Barman, Lorenzo Cavagna.; Yogesh Preet Singh, ; Patel, Aarat; Chatterjee, Tulika; Nune, Arvind; James, B Lilleker; John, D Pauling; Armen Yuri Gasparyan, ; Saavedra, Miguela; Antonio Fraga Mouret, ; Abraham Edgar Gracia Ramos, ; 12 of 14 International Journal of Rheumatic Diseases, ; 2025Erick Adrian Zamora Tehozol, ; Jorge Rojas Serrano, ; Ignacio GarcíaDe La Torre, ; Colunga Pedraza, Iris J.; Javier Merayo Chalico, ; Phonpen Akawatcharangura Goo, ; Katchamart, Wanruchada; Russkashumnalieva, ; Chen, Yi-Ming; Gheita, Tamer; Mohammedfathi, Hanan; Reem Hamdy, A Mohammed; Leonardo Santos Hoff, ; ManuelFrancisco Ugarte- Gil, ; Chinchay, Lyn; José Proaño Bernaola, ; Victoriopimentel, ; Lina El Kibbi, ; Halabi, Hussein; Milchert, Marcin; Raquelaranega, ; Loarce-Martos, Jesús; Sergio Prieto- González, ; Vaidya, Binit; Tanveer Hasan, A. T. M.; Hudson, Marie; Océane Landon- Cardinal, ; Lilith Stange Nunez, ; Cristian Vergara, M; Calapaqui, Wendy; Ivonnequezada, ; Lisa, S Traboco; Salim, Babur; Rodrigo García Salinas, ; Yurilís Fuentes- Silva, ; Harifi, Ghita; Nagy-Vincze, Melinda; Gromova, Margaritaaleksandrovna; Other COVADInvestigators: Rajiv Ranjan, Jossiell Then Báez.; Jain, Avinash; Sapan, C Pandya; Pilania, Rakeshkumar; Sharma, Aman; Manesh Manoj, M; Gupta, Vikas; Chengappa, G Kavadichanda; Pradeepta Sekhar Patro, ; Ajmani, Sajal; Phatak, Sanat; Rudra Prosad Goswami, ; Abhra Chandra Chowdhury, ; Ashish Jacob Mathew, ; Shenoy, Padnamabha; Asranna, Ajay; Bommakanti, Keerthitalari; Shukla, Anuj; Arunkumar, R Pande; Kunalchandwar, ; Ghodke, Akanksha; Nicoletta Del Papa, ; Gianlucasambataro, ; Fabiola, Atzeni; Govoni, Marcello; Parisi, Simone; Bocci, Elenabartoloni; Griger, Zoltán; Gian Domenico Sebastiani, ; Enricofusaro, ; Sebastiani, Marco; Quartuccio, Luca; Franceschini, Franco; Pier Paolo Sainaghi, ; Orsolini, Giovanni; Rossella De Angelis, ; Danielli, Mariagiovanna; Venerito, Vincenzo; Grignaschi, Silvia; Alessandrogiollo, ; Alluno, Alessia; Ioannone, Florenzo; Fornaro, Marco; Okwara Celestine Chibuzo, ; Ima-Edomwonyi, Uyi; Ibukunoluwadedeke, ; Airenakho, Emorinken; Nwankwo Henry Madu, ; Abubakaryerima, ; Olaosebikan, Hakeem; Wilmer Gerardo Rojas, ; Álvaroarbeláez, ; Cajas, Javier; Alejandro Quiñónez Obiols, ; Chávez, Nilmo; Andrea Bran Ordóñez, ; Argueta, Sandra; Quijivix, Daniel; Damanlangguth, ; Limaye, Vidya; Needham, Merrilee; Srivastav, Nilesh; Yoshida, Akira; Nakashima, Ran; Sato, Shinji; Kimura, Naoki; Yukokaneko, ; Gono, Takahisa; Cachafeiro-Vilar, Antonio; Guerrabautista, Generoso; Enrique Julio Giraldo Ho, ; Hmamouchi, Ihsane; Bouchti, Imaneel; Baba, Zineb; Kardes, Sinan; Dondu Uskudar Cansu, ; Yildirim, Resit; Tomaras, Stylianos; Fabian Nikolai Proft, ; Holzer, Marie-Therese; Arrieta, Dina; Eduardo Romero Hidalgo, ; Ricardosaenz, ; Giannini, Margherita; Maurier, François; Campagne, Julien; Meyer, Alain; Arredondo, Gabriela; José António Pereira Silva, ; Fonseca, Joãoeurico; Ouma Devi Koussougbo, ; Cabriza, Karoll; Jonathanlosanto, ; Colaman, Nelly; Distler, Oliver; Becky, A.; Alonzo, Hugo; Elena Nikiphorou, Carlos Benito Santiago Pastelin.; Parodis, Ioannis; Velikova, Tsvetelina; Abraham Edgar Gracia-Ramos, ; Masatakakuwana, ; Knitza, Johannes; Makol, Ashima; Carlos Enrique ToroGutiérrez, ; Dey, Dzifa; Day, Jessica; Wincup, Chris; Dalbeth, Nicola; Burmester, Gerd-Rüdige
Link alla scheda completa:
Pubblicato in: